Hormone receptor in triple-negative breast cancer
1 EU-approved indication in triple-negative breast cancer needs a Hormone receptor result: datopotamab deruxtecan (1st line, advanced).
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| ER/PR/HER2 negative1 | ||||
Datroway | Triple-negative (ER-negative, PR-negative, HER2-negative) | Monotherapy | 1L advanced | Not candidates for PD-1/PD-L1 inhibitor therapy |
4 approvals for TNBC need no biomarker and apply whatever the result. All approvals for TNBC
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Datopotamab deruxtecan (Datroway)
Datroway as monotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy (see section 5.1).